{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:13:32Z","timestamp":1788542012827,"version":"build-2803163510"},"reference-count":45,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"unspecified","delay-in-days":65,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pear Therapeutics, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2021,5,19]]},"DOI":"10.1080\/00325481.2021.1884471","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T02:50:54Z","timestamp":1613703054000},"page":"421-427","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder"],"prefix":"10.1080","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-5933","authenticated-orcid":false,"given":"Fulton F.","family":"Velez","sequence":"first","affiliation":[{"name":"Medical Affairs, Research and Development, Pear Therapeutics, Inc, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary F.","family":"Luderer","sequence":"additional","affiliation":[{"name":"Medical Affairs, Research and Development, Pear Therapeutics, Inc, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gerwien","sequence":"additional","affiliation":[{"name":"Medical Affairs, Research and Development, Pear Therapeutics, Inc, Boston, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-7007","authenticated-orcid":false,"given":"Benjamin","family":"Parcher","sequence":"additional","affiliation":[{"name":"Formerly with Xcenda, LLC., Palm Harbor, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Mezzio","sequence":"additional","affiliation":[{"name":"Formerly with Xcenda, LLC., Palm Harbor, FL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5006-9394","authenticated-orcid":false,"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[{"name":"Strategic Therapeutics, LLC., Oro Valley, AZ, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"cit0001","unstructured":"Center for Disease Control and Prevention (CDC). Opioid Overdose. Understanding the Epidemic [Cited 2020 Dec 3]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html."},{"key":"cit0002","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2018 on CDC WONDER Online Database, released January, 2020 [Cited 2020 Dec 3]. Available from: https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics\/overdose-death-rates."},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0898-0"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1210"},{"key":"cit0005","unstructured":"Centers for Disease Control and Prevention (CDC). Health advisory (CDCHAN-00438). Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic. 2020 [Cited 2021 Jan 5]. Available from: https:\/\/emergency.cdc.gov\/han\/2020\/han00438.asp?ACSTrackingID=USCDC_511-DM44961&ACSTrackingLabel=HAN%20438%20-%20General%20Public&deliveryName=USCDC_511-DM44961."},{"key":"cit0006","unstructured":"The Opioid Response Network. The opioid epidemic and COVID-19: how social determinants of health create differential impacts. 2020 [Cited 2021 Jan 5]. Available from: https:\/\/opioidresponsenetwork.org\/documents\/SDH_OUD-COVID-19.pdf"},{"key":"cit0007","unstructured":"American Medical Association (AMA). Issue brief: reports of increases in opioid-related overdose during COVID pandemic. 2020 [Cited 2020 Dec 3]. Available from: https:\/\/www.ama-assn.org\/system\/files\/2020-11\/issue-brief-increases-in-opioid-related-overdose.pdf."},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108176"},{"key":"cit0009","unstructured":"Society of Actuaries. Economic Impact of Non-Medical Opioid Use in the United States [Cited 2020 Dec 3]. Available from: https:\/\/www.soa.org\/globalassets\/assets\/files\/resources\/research-report\/2019\/econ-impact-non-medical-opioid-use.pdf."},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"cit0011","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). 2019 [Cited 2020 Dec 3]. Available from: www.samhsa.gov\/data\/."},{"issue":"6","key":"cit0012","first-page":"e172","volume":"23","author":"Ruetsch C","year":"2017","journal-title":"Am J Manag Care"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S150253"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1186\/1940-0640-9-16"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1840357"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2020.1824236"},{"key":"cit0018","unstructured":"Centers for Disease Control and Prevention (CDC). Opioid Overdose: Assessing and Addressing Opioid Use Disorder (OUD). 2018 [Cited 2021 Jan 5]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/training\/oud\/accessible\/index.html"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.31478\/202004b"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"cit0021","unstructured":"NIDA. 2020, June 1. Community Reinforcement Approach Plus Vouchers (Alcohol, Cocaine, Opioids)[Cited 2020 Dec 3]. Available from: https:\/\/www.drugabuse.gov\/publications\/principles-drug-addiction-treatment-research-based-guide-third-edition\/evidence-based-approaches-to-drug-addiction-treatment\/behavioral-therapies\/community-reinforcement-approach-vouchers."},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500150065028"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2012.03.009"},{"key":"cit0024","unstructured":"Pear Therapeutics Inc. reSET-O - Clinician Instructions for Use. 2019 [Cited 2020 Aug 17]. Available from: https:\/\/peartherapeutics.com\/wp-content\/uploads\/2019\/08\/PEAR-MKT-025-reSET-O-Clin-Brief-Sum_Dec2019.pdf."},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1007\/s40429-020-00344-6"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.10.014"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1846023"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1858581"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1037\/a0037496"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1846022"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03299.x"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31814848f1"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-4"},{"key":"cit0034","unstructured":"IBM Micromedex RED BOOK [Internet]. IBM Watson Health\u2122, an IBM Company; c2017. [cited 2019 Feb 20]. Available from: https:\/\/www.ibm.com\/us-en\/marketplace\/micromedex-red-book."},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.01913.x"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2014.12092.x"},{"key":"cit0037","unstructured":"Institute for Clinical and Economic Review (ICER). Extended-Release Opioid Agonists and Antagonist Medications for Addiction Treatment (MAT) in Patients with Opioid Use Disorder: Effectiveness and Value. 2018 [Cited 2020 Dec 3]. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2018\/04\/ICER_Opioid_Use_Disorder_Draft_Evidence_Report_090718-1.pdf."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.16.2.132"},{"issue":"12","key":"cit0039","first-page":"e11863","volume":"12","author":"Proctor R","year":"2020","journal-title":"Cureus"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.08.002"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.05.015"},{"issue":"3","key":"cit0042","first-page":"163","volume":"79","author":"Morse ED","year":"2018","journal-title":"N C Med J"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.3111\/13696990701605235"},{"issue":"11","key":"cit0044","first-page":"e11311","volume":"12","author":"Sulley S","year":"2020","journal-title":"Cureus"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1111\/add.13219"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2021.1884471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T18:21:29Z","timestamp":1619979689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2021.1884471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5,19]]}},"alternative-id":["10.1080\/00325481.2021.1884471"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2021.1884471","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}